消癌平注射液联合TACE治疗晚期原发性肝癌的临床疗效及安全性研究  

Clinical efficacy and safety of TACE combined with TACE for advanced primary liver cancer

作　　者：徐建林[1] 郑瑞锋[1] 王彦威[1] XU Jianlin;ZHENG Ruifeng;WANG Yanwe(Cancer Department of Hematology,Henan general team Hospital of armed police force,Zhengzhou,Henan,45005)

机构地区：[1]武警河南总队医院,450052

出　　处：《首都食品与医药》2018年第17期61-62,共2页Capital Food Medicine

摘　　要：目的探讨消癌平注射液联合TACE治疗晚期原发性肝癌的临床疗效及安全性。方法选取我院收治的晚期原发性肝癌112例,随机分为两组,对照组患者应用TACE治疗,研究组患者应用消癌平注射液联合TACE治疗。结果研究组患者的治疗效果明显优于于对照组(P<0.05);研究组的不良反应明显低于对照组(P<0.05)。结论晚期原发性肝癌的治疗过程当中,消癌平注射液联合TACE治疗法的治疗效果理想,临床上应当进一步推广应用。Objective To investigate the clinical efficacy and safety of TACE combined with TACE for advanced primary liver cancer. Methods 112 patients with advanced liver cancer were selected from March 2015 to March 2016 in our hospital, randomly divided into two groups, the control group was treated with TACE, and the group was treated with anti- cancer fiat injection combined with TACE. Resu Its The treatment effect of the study group was better than that of the control group （P 〈 0.05）. The adverse reactions of the study group were significantly lower than the control group （P 〈 0.05）. Conclusion In the course of treatment of advanced primary hepatocellular carcinoma, the therapeutic effect of combined TACE therapy combined with anti-cancer injection is ideal, and the application should be further promoted clinically.

关 键 词：消癌平注射液 TACE治疗 晚期 原发性肝癌 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]